Clinical Pioneer Awards

Through the scheme we will fund innovative project ideas that are focused on practical interventions within the clinical or community setting that can be adopted in an optimal pancreatic cancer pathway.

We are committed to ensuring that everyone affected by pancreatic cancer receives the best standard of care, treatment and support in order to live as long and as well as possible regardless of where they live in the UK. We need to dramatically transform the patient experience of pancreatic cancer, transforming the culture of treatment from defeatism to optimism. This is why we have established our Clinical Pioneer Awards scheme. Through the scheme we will fund innovative project ideas that are focused on practical interventions within the clinical or community setting that can be adopted in an optimal pancreatic cancer pathway. Such interventions can include drive down waiting times (time to diagnosis; time to treatment; time to referral), improve survival, quality of life and patient experience and deliver a consistent standard of care for people affected by pancreatic cancer.


Key priority areas

Below are the key priority areas for the Clinical Pioneer Award Scheme 2019. These were chosen based on optimal care pathway development by Pancreatic Cancer UK and our ‘Promoting Innovative Practice’ initiative which shows examples of innovative practice that already exists in the field.

Funding is awarded to projects that address one of the key priority areas listed below. Applicants are asked to demonstrate how their application would target one of these areas:

Diagnostic pathway:

  • Rapid access clinic for vague symptoms e.g. rapid access jaundice clinic
  • One stop clinic
  • PET-CT scanning integration within diagnostic pathway

Treatment pathway:

  • Audit/review/redesign of processes for informed treatment and care decision making
  • Develop models of fast track treatments at the surgical and oncological setting so that patients are treated faster and safely (e.g. straight to surgery, neoadjuvant approach, radiation therapy, adjuvant chemotherapy and palliative oncology)
  • Develop centralised oncology pathways for inoperable pancreatic cancer patients
  • Scoping staffing resource needed to support treatment pathways (e.g. CNS, patient navigator/coordinator)

Supportive care pathway:

  • Prehabilitation/rehabilitation (this can include symptom management, physical fitness, nutritional and mental health and well-being optimisation)
  • Enhanced recovery after surgery
  • Quality of life metric development
  • Specialised psychological support service or intervention

Key details

Where: Projects should be hosted within a UK NHS organisation or research institution (with wider collaborations where appropriate).

Who: Funding will be awarded to a team led by one Lead applicant, with broad and appropriate expertise and a strong track record in engaging with key stakeholders, and testing and applying interventions in practice.

Funding available: In 2019/20 at total of £200,000 is available. Funding will be awarded to a maximum of 4 awards.

For each award, a total of up to £50,000 is available to support directly incurred research costs for up to 12 months.

Duration: Up to 12 months

Key dates

This scheme is now closed for applications.

Before you apply

For more information about the eligibility criteria for this round and detail on the key areas to address in the application, please read the guidance notes.

All potential applicants and their Host Institutions should ensure that they have reviewed Pancreatic Cancer UK’s Terms and Conditions, which set out the standard terms applicable to all research grants funded by Pancreatic Cancer UK.


How to apply

To submit your application for funding, please complete the application form and email before the application deadline.

All applications for funding are subject to a rigorous review process to identify proposals with the best chances of making a difference to people affected by pancreatic cancer. A final funding recommendation will be made by the Clinical Pioneer Award Review Panel.


For any queries relating to this fund, please email or call the research team on 020 7820 6705